Gustafsen J, Lendorf A, Raskov H, Boesby S
Scand J Gastroenterol. 1986 Sep;21(7):816-8. doi: 10.3109/00365528609011123.
Seven patients, four women and three men, with a median age of 64 years (range, 53-74 years) were randomized to treatment with either ketanserin, 40-160 mg daily, or placebo. The study included 13 treatment periods with ketanserin and 13 with placebo. All patients had typical symptoms, with flushing as their main complaint. The diagnosis had been verified histologically. All had elevated excretion of 5-hydroxy-3-indoleacetic acid in urine. During the trial ketanserin reduced the number of flushing attacks in five patients (p less than 0.05). Diarrhoea was reduced in two patients. No side effects were observed. Ketanserin seems valuable for the symptomatic relief in the carcinoid syndrome.
7名患者（4名女性，3名男性），中位年龄64岁（范围53 - 74岁），被随机分为两组，分别接受每日40 - 160毫克酮色林治疗或安慰剂治疗。该研究包括13个使用酮色林的治疗周期和13个使用安慰剂的治疗周期。所有患者均有典型症状，主要症状为面部潮红。诊断已通过组织学证实。所有患者尿中5 - 羟色胺酸排泄量均升高。在试验期间，酮色林使5名患者的面部潮红发作次数减少（p < 0.05）。2名患者腹泻症状减轻。未观察到副作用。酮色林似乎对缓解类癌综合征的症状有价值。
